Statement regarding share price

RNS Number : 3474K

hVIVO plc

10 April 2018

 

For immediate release 7.00am: 10 April 2018

HVIVO PLC

("hVIVO" or the "Company")

 

Statement regarding share price

The Board of hVIVO plc (AIM: HVO) notes the sudden and extreme fall in its share price in recent days and confirms that it knows of no reason for such a fall.

The Company announced initial results on 26 March 2018 of a Phase IIb study examining FLU-v as a potential universal vaccine against influenza (flu) which, although only indicating a trend to statistical significance of the primary endpoint, did demonstrate a statistically significant reduction in overt flu symptoms and gives the Board cause for optimism that its investment in FLU-v (through its joint venture Imutex Limited) has potentially significant future value.

The Company will announce its audited preliminary results for the year ended 31 December 2017 on 19 April 2018.  Financial results for the year ended 31 December 2017 are expected to be in-line with market expectations, with cash as at 31 December 2017 of £20.3 million (2016: £25.7 million) which is markedly ahead of expectations.

For further information please contact:

hVIVO plc	[phone]
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries	[phone]
Susan Flood
Numis Securities Limited	[phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK)	[phone]

Notes to Editors:

About hVIVO plc

hVIVO plc ("hVIVO") is developing a pioneering human-based analytical platform to accelerate drug discovery and development in airways diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

 

END

 

 

SPMILMBTMBJMTLP